Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Reviewer: S. Jack Wei, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 13 de octubre del 2004
Presenter: M. Stuschke
Presenter's Affiliation: University of Essen, Essen, Germany (German Multicenter Trial)
Type of Session: Scientific
Materials and Methods
The current study demonstrates that in locally advanced SCCA of the esophagus, surgical resection does not provide a survival benefit over definitive radiochemotherapy. There was however, an improvement in local control with surgery. This benefit was largely offset by the increased treatment-related mortality due to surgery. It should be noted that although more patients died initially in the surgery arm, there was a trend towards an increased rate of long-term survival with surgery. In addition, a steep learning curve with regards to surgery was seen: the majority of surgery-related mortality occurred in the first half of the study duration. Presumably, if patients are carefully selected with regards to their ability to withstand surgical resection, and surgical techniques and post-operative care improves, the trend towards improved long-term survival with surgery may translate into a significant overall survival benefit. This may be particularly true for patients who do not show any response to the induction portion of RTCT.
The results of this study are in contrast to a recently reported French study also comparing neoadjuvant RTCT followed by surgery with definitive RTCT. The results of that trial showed improved median and 2-year overall survival for patients receiving definitive RTCT (17.7 mo vs. 19.3 mo and 34% vs. 40%, respectively). However, patients in that study who received definitive RTCT had a higher rate of dilation and stent requirement compared to those undergoing surgery. The French study and the current study demonstrate that the decision to treat with surgery or definitive RTCT should be individualized, and surgical resection should be reserved for carefully selected patients.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults